Overview

Glucocorticoid on the Prognosis of TEVAR

Status:
Unknown status

Trial end date:
2019-09-01

Target enrollment:

Participant gender:

Summary

To explore the potential prognostic effect of glucocorticoid on the postoperative aorta-related adverse events after aortic dissections patients underwent thoracic endovascular aortic repair (TEVAR), glucocorticoid (30mg/kg) will be intravenously given within 2h after TEVAR.

Phase:

N/A

Details

Lead Sponsor:

Changhai Hospital

Treatments:

Glucocorticoids
Methylprednisolone